The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics

British Journal of Dermatology

Volumn 162, Issue 6, 2010, Pages 1324-1329

  Driessen, R J B ^a   Bisschops, L A ^a   Adang, E M M ^a   Evers, A W ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biologic; Costs; Effectiveness; Psoriasis; Satisfaction; Treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID; PSORALEN; TACROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUESTIONNAIRE;

ADULT; AGED; BIOLOGICAL PRODUCTS; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77952695421     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09693.x     Document Type: Article

References (18)

1. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 407.
2. Chan B, Hales B, Shear N et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009 13 : 192 197.
3. Colombo G, Altomare G, Peris K et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008 4 : 559 568.
4. Fowler JF, Duh MS, Rovba L et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008 59 : 772 780.
5. Sizto S, Bansback N, Feldman SR et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009 160 : 1264 1272.
6. Sohn S, Schoeffski O, Prinz J et al. Cost of moderate to severe plaque psoriasis in Germany: A multicenter cost-of-illness study. Dermatology 2006 212 : 137 144.
7. Feldman SR, Fleischer AB Jr., Reboussin DM et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997 37 : 564 569.
8. Bansback N, Sizto S, Sun H et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis. Dermatology 2009 219 : 209 218.
9. Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008 159 : 513 526.
10. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 23 (Suppl. 2 1 70.
11. Stichting Farmaceutische Kengetallen. Data en Feiten 2009.
12. Bhosle MJ, Feldman SR, Camacho FT et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006 17 : 294 301.
13. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
14. Atkinson MJ, Kumar R, Cappelleri JC et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005 8 (Suppl. 1) : S9 24. Those seeking information regarding or permission to use the TSQM are directed to Quintiles, Inc. at http://www.quintiles.com/TSQM (last accessed 25 February 2010) or.
15. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg, Geactualiseerde versie 2004.
16. Richtlijnen en Protocollen in de Dermatologie. Richtlijn: Foto(chemo)therapie en systemische therapie bij ernstige chronische plaque psoriasis. Herziene versie 2005.
17. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 2009 20 : 42 7.
18. Javitz HS, Ward MM, Farber E et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002 46 : 850 860.